The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis

Aims. Recent randomised controlled trials (RCTs) have shown a significant prognostic benefit of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the cardiovascular (CV) profile of patients with diabetes. This systematic review and meta-analysis aim to provide a concise evaluation of all the avai...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vasiliki Tsampasian, Ranu Baral, Rahul Chattopadhyay, Maciej Debski, Shruti S Joshi, Johannes Reinhold, Marc R Dweck, Pankaj Garg, Vassilios S Vassiliou
Format:	Article
Language:	English
Published:	Wiley 2021-01-01
Series:	Cardiology Research and Practice
Online Access:	http://dx.doi.org/10.1155/2021/9927533
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Valvular Cardiomyopathy: The Value of Cardiovascular Magnetic Resonance Imaging
by: Vasiliki Tsampasian, et al.
Published: (2022-01-01)

The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01)

Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials
by: Miao Lin, et al.
Published: (2025-02-01)

The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
by: Wenjun Sha, et al.
Published: (2020-01-01)

Research Progress of SGLT2 Inhibitors in Cancer Treatment
by: Miao X, et al.
Published: (2025-01-01)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
by: Qasim Zafar Iqbal, et al.
Published: (2020-01-01)

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

BDNF Levels and Cognitive Function in Patients with Type 2 Diabetes Treated with SGLT2 Inhibitors
by: Betül SÜMBÜL ŞEKERCİ, et al.
Published: (2025-01-01)

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice
by: Weiling Leng, et al.
Published: (2016-01-01)

Bilateral De Quervain Syndrome after Aromatase Inhibitor Administration: A Case Report and Review of the Literature
by: Konstantinos Papadimitriou, et al.
Published: (2012-01-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
by: Pasquale Paolisso, et al.
Published: (2024-11-01)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
by: Kris Aubrey-Bassler, et al.
Published: (2019-02-01)

The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

The Use of SGLT-2 Inhibitors and GLP-1RA in Frail Older People with Diabetes: A Personalised Approach Is Required
by: Alan J. Sinclair, et al.
Published: (2025-01-01)

Optimización SGLT2 para cardionefro protección
by: Yukiko Harumi Yamasaki Ramos, et al.
Published: (2025-01-01)

Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
by: Sanbao Chai, et al.
Published: (2024-01-01)

Correction: SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI)
by: Pasquale Paolisso, et al.
Published: (2025-01-01)

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
by: Apichaya Chanawong, et al.
Published: (2023-01-01)

Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
by: Haoyi Yang, et al.
Published: (2025-01-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of Atrial Fibrillation in patients with type 2 diabetes mellitus: a meta-analysis
by: Xiaoyan Liang, et al.
Published: (2025-01-01)

From bench to bedside: elucidating VEGF(R) inhibitor-related heart failure in cancer treatment
by: Shengkun Peng, et al.
Published: (2025-01-01)

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
by: Jun Muneuchi, et al.
Published: (2022-01-01)

Mitochondrial insights on antidiabetic therapies: Differential impacts of SGLT2i, GLP-1, and insulin
by: Yu-Hsiang Lin, et al.
Published: (2025-02-01)

Heart Failure
by: Yanggan Wang, et al.
Published: (2014-01-01)

Echocardiographic assessment of aortic regurgitation: a practical guideline from the British Society of Echocardiography
by: Kelly Victor, et al.
Published: (2025-01-01)

Characterization of heart failure patients with reverse left ventricular remodelling post‐angiotensin receptor blockers/neprilysin inhibitors therapy
by: Leonid Maizels, et al.
Published: (2022-06-01)

Lungs in Heart Failure
by: Anna Apostolo, et al.
Published: (2012-01-01)

CMR in Heart Failure
by: Daniel M. Sado, et al.
Published: (2011-01-01)

Heart Failure 2012
by: Gregory Giamouzis, et al.
Published: (2012-01-01)

The Molecular Effects of SGLT2i Empagliflozin on the Autophagy Pathway in Diabetes Mellitus Type 2 and Its Complications
by: Ranin Saad, et al.
Published: (2022-01-01)

CMR Features in Cardiac Sarcoidosis
by: Sparsh Prasher, et al.
Published: (2011-01-01)

Lipoprotein(a) and other risk factors in dyslipidemic patients with and without heart failure
by: Joanna Lewek, et al.
Published: (2024-10-01)

An overlapping sliding window and combined features based emotion recognition system for EEG signals
by: Shruti Garg, et al.
Published: (2025-01-01)

GLP-1 and SGLT2 Therapies in Type 2 Diabetes Mellitus. Cutting-Edge Approaches to Advancing Diabetes Care
by: Agnieszka Parfianowicz, et al.
Published: (2025-02-01)

Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells
by: Aiko Seki, et al.
Published: (2025-01-01)

Cognitive Impairment in Heart Failure
by: Efthimios Dardiotis, et al.
Published: (2012-01-01)